SCHEMBL2706554

SCHEMBL2706554

O=CNc1cnc2ccccc2c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
PABPC1 P11940 1/20 0.39
KDM4E B2RXH2 2/20 0.39
GPR3 P46089 1/20 0.39
HDAC6 Q9UBN7 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
PTPN1 P18031 1/20 0.35
PTPN11 Q06124 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HTR1A P08908 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27747272 0.78 KDM4E (0.36) PABPC1KDM4EALDH1A1ADRA1DADRA1A
SCHEMBL843955 0.77 ERN1 (0.50) ERN1MAOAMAOBKDM4EGPR3
SCHEMBL18874674 0.76 ERN1 (0.49) ERN1MAOAMAOBKDM4EGPR3
SCHEMBL2707298 0.74 KMT2A (0.55) PABPC1KDM4EALDH1A1HPGDALOX15
SCHEMBL2002464 0.74 HTR1A (0.58) PABPC1HDAC6PTPN1PTPN11HTR1A
SCHEMBL28835909 0.72 PRKCI (0.54)
SCHEMBL21781663 0.72 GRM5 (0.54)
SCHEMBL2709340 0.72 ALDH1A1 (0.46) PABPC1KDM4EALDH1A1MAPT
SCHEMBL20564258 0.72 ALDH1A1 (0.59) KDM4EALDH1A1CYP1A2CYP2C19MEN1
SCHEMBL2708169 0.72 BCHE (0.56) PABPC1HDAC6ALDH1A1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1789042-B1 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2012-05-02 EP disclosed
US-20090240055-A1 Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof KREPSKI LARRY R 2009-09-24 US disclosed
US-7579359-B2 1-alkoxy 1H-imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-08-25 US disclosed
EP-1789042-A4 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2009-07-22 EP disclosed
US-20090005376-A1 imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2009-01-01 US disclosed
EP-1937683-A1 METHOD FOR 1H-IMIDAZOÝ4,5-c¨PYRIDINES AND ANALOGS THEREOF Coley Pharmaceutical Group, Inc. (US) 2008-07-02 EP disclosed
EP-1789042-A2 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-30 EP disclosed
WO-2007035935-A1 METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-03-29 WO disclosed
WO-2006028962-A2 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240055-A1 Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof CYP4B1, CYP4F8, CYP4X1 ERN1 2483/4885MAOA 195/4885MAOB 124/4885
US-20090005376-A1 imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases IL2, IL4, IRF3 ERN1 1609/4885MAOA 3970/4885MAOB 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.